Table 2.

BRAF mutation status and survival after CRC diagnosis by patient and tumor characteristics

Disease-specific survivalOverall survival
BRAF-wt deaths/casesBRAF-mut deaths/casesHR (95% CI)aPinteractionBRAF-wt deaths/casesBRAF-mut deaths/casesHR (95% CI)aPinteraction
Overall (unadjusted)413/1,73353/2470.95 (0.72–1.27)655/1,733102/2471.11 (0.90–1.38)
Overall (adjusted)413/1,73353/2471.43 (1.05–1.95)655/1,733102/2471.21 (0.96–1.54)
By age at diagnosis
 <50 y104/48014/293.06 (1.70–5.52)<0.001132/48014/292.12 (1.20–3.76)0.04
 ≥50 y309/1,25339/2181.23 (0.85–1.77)523/1,25388/2181.12 (0.86–1.46)
By sex
 Male200/83216/681.34 (0.79–2.27)0.99335/83232/681.27 (0.86–1.89)0.43
 Female213/90137/1791.50 (1.01–2.22)320/90170/1791.23 (0.91–1.67)
By tumor site
 Proximal152/59238/1921.27 (0.86–1.88)0.36243/59278/1921.22 (0.91–1.64)0.97
 Distal/rectal254/1,09914/491.76 (1.00–3.10)395/1,09920/491.25 (0.78–2.00)
By stage at diagnosis
 Localized46/6901/950.20 (0.03–1.58)165/69024/950.75 (0.44–1.25)
 Regional204/80439/1331.55 (1.07–2.27)0.07305/80461/1331.31 (0.96–1.79)0.23
 Distant161/21113/151.72 (0.92–3.24)173/21114/151.57 (0.85–2.91)
By MSI
 MSS375/1,49438/1091.62 (1.16–2.26)0.17581/1,49449/1091.23 (0.91–1.65)0.85
 MSI-H22/17114/1260.94 (0.44–2.03)49/17151/1261.17 (0.75–1.81)
  • aAdjusted for age at diagnosis, sex, time from diagnosis to enrollment, stage, and MSI status unless otherwise noted. All associations are relative to BRAF-wild-type case group.